Specialized Medical Services-oncology BV (SMS-oncology), a full service CRO specialized in clinical drug development studies in oncology and hematology, today announced that, according to the business planning, a strong growth in 2015 was accomplished. The growth, comprising both an increase in revenue and employment base, confirms that SMS-oncology is on track in realizing its ambition to become a leading European oncology CRO. It highlights that 2015 was a good year for SMS-oncology as underpinned by significant improvements that have been made throughout the corporate framework. This includes the set-up of a data management unit in house - in Amsterdam - offering clients an affordable data management solution, according to CDISC standards, perfectly suiting the needs of early phase oncology trials.
It was also the year of implementing SMS-oncology’s 4D service: providing Direction to sponsors along the value chain from Drug to Data to Dossier. This unique value proposition of providing frequent ‘Insights & Analytics Reports’ is an extra service. Using their oncology know-how and expertise, SMSoncology consultants are able to dive deep into the data, crunch it and thereby turn this often complex data into meaningful insights. By intertwining clinical operations and data management with medical affairs and consultancy capabilities, SMS-oncology offers upside potential to sponsors as it will allow them to be on top of the data and in charge of the progress in the development of their oncology drug.
To further extend the expert advice, operational competences and to support the future growth, SMS-oncology is very pleased to announce that it will start its ‘Oncology Clinical Research Associate (CRA) Academy’ as of April 2016. SMS-oncology is hereby taking the lead in training motivated young healthcare professionals through a comprehensive, individualized and hands-on training program in becoming oncology CRAs.
Furthermore, the team of Operational Directors will be strengthened by Stephan Winckels taking on the role of Director Medical Affairs as of February 2016. Trained as an MD and with a PhD in Medical Physiology, Stephan jumpstarted his pharmaceutical career as Medical Monitor in 2009. Following different positions in the last 7 years as safety physician and clinical project manager/monitor for oncology studies in the pharmaceutical and CRO arena, Stephan gained strong experience in clinical oncology drug development. His expertise and operational insights will be of great value in performing thorough medical reviews and giving expert advice ultimately benefitting our clients in achieving their clinical goals.
In addition, current Chief Operating Officer (COO) Philine van den Tol will succeed Edwin Klumper, cofounder and shareholder of SMS-oncology, in the position of Chief Executive Officer (CEO). Edwin will take on the role of Chief Medical Officer (CMO). Edwin is pleased to pass on the baton to Philine and convinced her passionate commitment will contribute to SMS-oncology’s continued growth:
“As of 2012, Philine has successfully led the company and supervised the Clinical Operations group supporting all studies with her substantial experience in managing early and late phase oncology trials. Bringing nearly 20 years of clinical cancer research experience to the table, sponsors benefit from her extensive expertise, strong oncology network and can-do attitude that is translated into the responsive and proactive culture and team at SMS-oncology. With her entrepreneurial sense and determination for excellence and client satisfaction, she has been the driving force in developing and implementing many improvements in processes and systems. Philine has earned the CEO position and is capable to realize the ambition for SMS-oncology to become a leading European oncology CRO”.
Philine is excited: “Our strong growth reflects that the oncology expertise, devotion and personal and professional attitude – the hallmarks of working with SMS-oncology – is appreciated by our sponsors and regarded to be of added value. We are in particular proud of the successful implementation of our 4D concept as the development of oncology drugs is highly complex and we’re able to support our clients to make informed decisions timely, stay in control, mitigate risks and identify any new opportunity. We are keen to continue last year’s good flow to further grow and pursue exceptional employee and client satisfaction”.
PDF for download
Please find our press release offered for download here:
SMS-oncology reports growth in 2015 (15 January 2016)